戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 for persistent innate immune responses after allogeneic cells.
2 accinated with irradiated syngeneic tumor or allogeneic cells.
3 ed p24 following stimulation with irradiated allogeneic cells.
4 /or epigenomic manipulation of autologous or allogeneic cells.
5 ize and eliminate infected, transformed, and allogeneic cells.
6 ns prevents macrophage-mediated rejection of allogeneic cells.
7  responses to pig cells are stronger than to allogeneic cells.
8 ith in vitro assays measuring the killing of allogeneic cells.
9 ber in vivo in response to immunization with allogeneic cells.
10     Each child received two infusions of the allogeneic cells.
11 when given before the first oral delivery of allogeneic cells.
12 F nor AH inhibited the CTL-mediated Lysis of allogeneic cells.
13 d-lymphocyte cultures against MHC-disparate (allogeneic) cells.
14 and the responses induced by the transfer of allogeneic cells, a murine model was used to characteriz
15                    To assess the survival of allogeneic cells after blood transfusion or transplantat
16 ncluding exosomes, are regularly released by allogeneic cells after transplantation.
17 cytes from BALB/c mice that were primed with allogeneic cells and conditioned with rapamycin in vivo
18                     Control animals rejected allogeneic cells and remained diabetic.
19 ly immunosuppressive to allow engraftment of allogeneic cells and they rely largely on graft-versus-l
20 onding cells in co-culture with x-irradiated allogeneic cells and which cause regulatory effects when
21 renatal transplantation of congenic or fully allogeneic cells are identical.
22              Regenerative therapies that use allogeneic cells are likely to encounter immunological b
23  consequences of alloimmune stimulation when allogeneic cells are transplanted to the liver in compar
24 tion and to induce immune tolerance to these allogeneic cells, as daily anti-rejection therapy cannot
25 himerism (MC), defined as the persistence of allogeneic cells at low concentrations, is well document
26 ministration of HLA-DQA1 in conjunction with allogeneic cells at the time of priming or at the time o
27 ession dramatically enhances the efficacy of allogeneic cell-based gene therapy for bone regeneration
28 etus and cancer cells to induce tolerance to allogeneic cell-based therapies by modifying cells to ex
29  potentially enabling the next generation of allogeneic cell-based therapies in oncology.
30 MHCs) in PSCs is particularly attractive for allogeneic cell-based therapies.
31 ide when administered in combination with an allogeneic, cell-based granulocyte-macrophage colony-sti
32 are developing MHC class II (MHC II)-matched allogeneic, cell-based uveal melanoma vaccines that acti
33 pients 1) proliferate weakly to donor strain allogeneic cells but vigorously to third-party strain ce
34 t NK cells at a resting state readily reject allogeneic cells, but not the skin allografts.
35 ietic stem cell transplant (HSCT) comprising allogeneic cells carrying a rare, naturally occurring, h
36 RA had microchimerism (Mc; pregnancy-derived allogeneic cells) carrying DERAA (DERAA-Mc) vs. 6% of he
37 t RAG(-/-) mice mount a specific response to allogeneic cells characterized by swelling and infiltrat
38                                              Allogeneic cells coated with anti-CTLA-4 Ab induced immu
39 versial, potentially limiting the success of allogeneic cell combination therapy (ACCT).
40                                       First, allogeneic cells convey risk reduction for recurrent mal
41  it is unclear whether priming with specific allogeneic cells could conversely elicit a viral peptide
42        Studies of cotransferred congenic and allogeneic cells demonstrated that bystander proliferati
43 eic transplanted thymi are not rejected, and allogeneic cells do not induce graft-versus-host disease
44  could be exploited therapeutically and that allogeneic cells engineered to express a chemorepellent
45 with T cell loss being sufficient for robust allogeneic cell engraftment.
46 lling HLA-G expression beyond EVT to protect allogeneic cells from immune rejection.
47 ll (ESC) products, immunological barriers to allogeneic cells, functional maturation beyond just the
48 ration of polyinosinic:polycytidylic acid or allogeneic cells (graft versus host).
49 n and inhibit T cells responding to adjacent allogeneic cells in a contact-independent manner via sec
50 d by NSCs are functional and can costimulate allogeneic cells in a mixed lymphocyte reaction.
51 proliferate in response to several different allogeneic cells in addition to 3B11.
52 urface of sperm, allowing them to survive as allogeneic cells in the female reproductive tract despit
53 ersistence of small numbers of fetal-derived allogeneic cells in the mother.
54  mice also stimulated greater responses from allogeneic cells in vitro.
55 re stimulated in vitro with anti-CD3 or with allogeneic cells in vivo in the presence or absence of r
56 and macrophages in recognizing and rejecting allogeneic cells in vivo.
57 k alloreactivity against recipient and other allogeneic cells, indicating a favorable safety profile
58                             When introducing allogeneic cells into chimeric recipients, concomitant t
59 r repair strategies may involve injection of allogeneic cells into inflamed regions of damaged tissue
60 n, we injected BLV-infected or mock-infected allogeneic cells into the shoulder of sheep in which an
61 o the host-vs-graft reaction toward injected allogeneic cells is also reduced.
62 s immune system after the transplantation of allogeneic cells is associated with wide-ranging side ef
63 r of HSCs (250 cells) and a subpopulation of allogeneic cells known to facilitate HSC engraftment (fa
64 (PSJLSV and BxSF11gSV) but could not kill an allogeneic cell line (C57SV).
65 onger response against DERAA(+) vs. DERAA(-) allogeneic cell lines in vitro, in line with an immunoge
66 nses, and these same effector cells can lyse allogeneic cell lines in vitro.
67 host's immune system, reducing the number of allogeneic cell lines required, and examine safety measu
68 mune system is naturally exposed to maternal allogeneic cells, maternal antibodies, and pathogens.
69                                    Moreover, allogeneic cell membranes manipulated to express xenopro
70                     Long-term engraftment of allogeneic cells necessitates eluding immune-mediated re
71 ng the first days of infection and show that allogeneic cells of the inoculum traffic from the vagina
72 ngs could be overcome by using prefabricated allogeneic cell or tissue products, but the vigorous imm
73 nstrate that iNKT cells are not activated by allogeneic cells per se, but expand, both in vitro and i
74 ganisms (zooids) by 14 d whereas transfer of allogeneic cell populations lacking MCs had only minimal
75 al upon thawing, providing an off-the-shelf, allogeneic cell product that can be developed into CAR-i
76                                              Allogeneic cell products so far have inferior persistenc
77   In contrast, CTLA4-Ig, which targets B7 on allogeneic cells, promotes long-term engraftment in thes
78  demonstrate that TheraCyte encapsulation of allogeneic cells provides robust immune protection in tr
79                        Immunomodulation with allogeneic cells rapidly and efficiently engineered to d
80 wever, in vivo priming of KbDb -/- mice with allogeneic cells resulted in strong CD8+ MHC class Ia-sp
81  (lasting >5 min) formed preferentially with allogeneic cells, resulting in diminished motility and s
82 unt immunity irrespective of the MHC-matched allogeneic cell's immunogenicity.
83                  Oral tolerance induced with allogeneic cells shares characteristics with antigen-spe
84                           On the other hand, allogeneic cells show several advantages over autologous
85 atal chondrocytes (NChons) are an attractive allogeneic cell source for cartilage repair, but their c
86 cept for the use of NIKS keratinocytes as an allogeneic cell source for the formation of bioengineere
87         NIKS keratinocytes are an attractive allogeneic cell source for this application.
88 ly focus on mesenchymal stem cells (MSCs) as allogeneic cell sources, based on availability and innat
89                                              Allogeneic cell stimulation used as a cell therapy may b
90 olytic CMV-specific responses using specific allogeneic cell stimulation, to confirm that this techni
91                                              Allogeneic cell therapeutics for cancer therapy or regen
92                          Immune rejection of allogeneic cell therapeutics remains a major problem for
93                       Genetic engineering of allogeneic cell therapeutics that fully prevents rejecti
94 y the immune hurdle of commercially scalable allogeneic cell therapeutics.
95 n and could contribute to the advancement of allogeneic cell therapeutics.
96 s9 while expressing a CAR to generate potent allogeneic cell therapies against HLA-E(+) solid tumors.
97                                              Allogeneic cell therapies can enable off-the-shelf produ
98                                              Allogeneic cell therapies have the potential to increase
99 jection, particularly for the advancement of allogeneic cell therapies.
100 rscore the importance of donor selection for allogeneic cell therapies.
101 g explored as an alternative cell source for allogeneic cell therapies.
102  the design and production of autologous and allogeneic cell therapies.
103 r improving the persistence of off-the-shelf allogeneic cell therapies.
104                                              Allogeneic cell therapy enables preoperative production
105 tentially represent a therapeutic advance in allogeneic cell therapy for cardiac repair.
106                               Autologous and allogeneic cell therapy for ischemic heart disease show
107                                     However, allogeneic cell therapy is limited by host patient immun
108                                   To address allogeneic cell therapy limitations, this study develope
109         Thus, systemic IL-15 used to support allogeneic cell therapy may paradoxically limit their th
110 stIL15-OPS-gammadelta T cells as a candidate allogeneic cell therapy platform combining direct cytoly
111 re being developed as the next generation of allogeneic cell therapy products.
112                                     Although allogeneic cell therapy should still be considered a "na
113 ssue-resident, are an emerging and versatile allogeneic cell therapy with potent anti-tumor activity,
114    This biologic feature can be exploited in allogeneic cell therapy, and the recognition of "missing
115  are emerging as the most promising means of allogeneic cell therapy.
116  progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immu
117          The capacity of killed or sonicated allogeneic cells to induce oral tolerance and enhance co
118 ell infusion revealed the early migration of allogeneic cells to peripheral lymphoid organs, with lat
119 tself to use of chimeric epidermis, cultured allogeneic cells, to provide short-term coverage, togeth
120                                           In allogeneic cell transfers, donor GFP+ splenocytes were d
121 fter either adult stem cell transplantation (allogeneic cell transplantation [ACT]; n = 18) or cord b
122                        We used syngeneic and allogeneic cell transplantation assays based on F344 rec
123 e suppression regimen that can be applied to allogeneic cell transplantation.
124                                              Allogeneic cells transplanted directly to the liver do n
125                                        While allogeneic cell transplants overcome the manufacturing c
126 ight circumvent the limitations and risks of allogeneic cell transplants.
127 in other mouse strains primed with different allogeneic cell types, including endothelial cells.
128 er delayed-type hypersensitivity response to allogeneic cells upon challenge but had normal contact h
129 the primary effector cells in the killing of allogeneic cells via "missing self" recognition.
130                              Higher doses of allogeneic cells were needed to produce equivalent engra
131                    The partially MHC-matched allogeneic cells were not detected in the blood or most
132 ormaldehyde-fixed, UVB-treated, or sonicated allogeneic cells were tested to determine if dead cells
133 f grafts 7 days after i.p. immunization with allogeneic cells, when CTL responses in L-selectin(-/-)
134  mechanisms regulating the behavior of these allogeneic cells, which are central to clinical applicat
135 ion of the MLR and CML responses of the same allogeneic cells with 200 times fewer modulator cells ne
136 e distinctive patterns of reactivity against allogeneic cells with different haplotypes.
137     The combination of prenatal tolerance to allogeneic cells with postnatal boosts in primed hosts m
138  the ability to implant either xenogeneic or allogeneic cells would greatly enhance the clinical appl

 
Page Top